Last reviewed · How we verify
NERVE GROWTH FACTOR
At a glance
| Generic name | NERVE GROWTH FACTOR |
|---|---|
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
- The Biopsychosocial Model to Identify Risk Factors for Chronic Post-traumatic Pain in ICU Patients
- AAV2-GDNF for Advanced Parkinson s Disease (PHASE1)
- Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (PHASE2)
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke (NA)
- A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NERVE GROWTH FACTOR CI brief — competitive landscape report
- NERVE GROWTH FACTOR updates RSS · CI watch RSS